[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580360":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":31,"locations":38,"responsibleParty":69,"collaborators":73,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":25,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":25,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":41,"whyStopped":25,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Karolinska Institutet","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Obesity medication liraglutide or semaglutide combined with digi-physical treatment Evira","ACTIVE_COMPARATOR","Patients randomized to this group will receive liraglutide or semaglutide in combination with a digi-physical treatment tool, named Evira. Patients will be provided with a digitless measuring scale intended for daily use at home. They will be able to communicate with clinical staff at pivotal moments.",[13,14],"Device: Digi-physical treatment tool, Evira","Drug: Obesity medication with liraglutide or semaglutide",{"label":16,"type":6,"description":17,"interventionNames":18},"Control group","Patients randomized to this group will receive liraglutide or semaglutide treatment according to the clinic's standard procedures.",[14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Digi-physical treatment tool, Evira","A digi-physical treatment tool named Evira will be used to provide behavioral treatment.",[9],null,{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":25},"DRUG","Obesity medication with liraglutide or semaglutide","Obesity medication with liraglutide or semaglutide according to the clinic's standard procedure",[16,9],[32],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Pernilla Danielsson Liljeqvist, Associate Professor","CONTACT","070-837 7734","46","pernilla.danielsson.liljeqvist@ki.se",[39,56],{"facility":40,"status":41,"city":42,"state":25,"zip":25,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"HKH Crown Princess Victoria's Childrens and youth Hospital Linköping","RECRUITING","Linköping","Sweden","SE",{"type":46,"coordinates":47},"Point",[48,49],15.62157,58.41086,{"lat":49,"lon":48},[52],{"name":53,"role":34,"phone":54,"phoneExt":36,"email":55},"Pär Andersson White, Medical doctor","010-103 00 00","par.andersson.white@liu.se",{"facility":57,"status":41,"city":58,"state":25,"zip":25,"country":43,"countryCode":44,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Ystad lasarett, Barn och ungdomsmedicinmottagningen","Ystad",{"type":46,"coordinates":60},[61,62],13.82041,55.42966,{"lat":62,"lon":61},[65],{"name":66,"role":34,"phone":67,"phoneExt":36,"email":68},"Annika Håkansson Rönnholm, RN","0411-99 51 40","annika.hakanssonhonnholm@skane.se",{"type":70,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Pernilla Danielsson","Principal investigator",[74],{"name":75,"class":76},"Evira AB","INDUSTRY","100580360","the-evira-study-additional-support-during-obesity-treatment-100580360",false,"NCT06836284","The Evira Study: Additional Support During Obesity Treatment","Evaluation of a Digital Treatment Tool in Combination With Obesity Medications","Inclusion Criteria:\n\n* Patients offered liraglutide or semaglutide in accordance with the clinic's routines.\n* Aged 12-17 years at the time of inclusion.\n* The family agrees to participate in a clinical study.\n\nExclusion Criteria:\n\n* Endocrine disorders other than well-controlled hypothyroidism.\n* Severe neuropsychiatric disorders that may affect adherence to the study.\n* Eating disorder requiring treatment within the last six months before inclusion or observed during screening prior to inclusion.\n* Somatic conditions that may complicate the evaluation of treatment outcomes, such as patients on irregular oral corticosteroid treatment.\n* Hypothalamic or monogenic obesity, and genetic syndromes such as Down syndrome.\n* Patients deemed unsuitable for participation by the responsible physician.","ALL","12 Years","17 Years",{"count":88,"type":89},40,"ESTIMATED","INTERVENTIONAL",[92],"NA","The goal of this clinical trial is to evaluate the effect of adding a digi-physical treatment tool as a complement to the local treatment with obesity medication in adolescents with obesity. The main question it aims to answer is:\n\n\\- Can a combination of a digi-physical treatment tool and obesity medication improve treatment outcomes for patients with obesity compared to patients treated with obesity medications alone?\n\nThis is a randomized controlled two-arm multicenter study where participants will be randomized to the intervention group (digi-physical treatment+medication) or control group (medication only). Participants will be followed for six months.",[95,96],"Childhood Obesity","Treatment Adherence",[98,99,100,101],"Mobile Health","Self-Monitoring","Digital Treatment","Anti-Obesity Medication","2026-04-29",{"date":104,"type":105},"2026-05-05","ACTUAL",{"date":107,"type":105},"2026-02-13",{"date":109,"type":89},"2027-05-01",{"name":5,"class":6},2]